Total Payments
$1,287
2024 Payments
$149.46
Companies
18
Transactions
64
Medicare Patients
9,366
Medicare Billing
$950,296
Payment Breakdown by Category
Food & Beverage$1,175 (91.3%)
Education$111.95 (8.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,175 | 61 | 91.3% |
| Education | $111.95 | 3 | 8.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $195.53 | 11 | $0 (2018) |
| Keryx Biopharmaceuticals, Inc. | $156.80 | 9 | $0 (2018) |
| Vifor Pharma, Inc. | $126.36 | 2 | $0 (2024) |
| Mallinckrodt LLC | $124.31 | 4 | $0 (2018) |
| Relypsa, Inc. | $100.29 | 5 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $86.00 | 3 | $0 (2018) |
| Amgen Inc. | $80.63 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $75.65 | 4 | $0 (2018) |
| Fresenius USA Marketing, Inc. | $68.76 | 4 | $0 (2018) |
| AKEBIA THERAPEUTICS INC | $65.33 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.46 | 3 | Vifor Pharma, Inc. ($104.82) |
| 2023 | $41.89 | 2 | Vifor Pharma, Inc. ($21.54) |
| 2019 | $36.95 | 2 | AKEBIA THERAPEUTICS INC ($20.37) |
| 2018 | $471.68 | 28 | Otsuka America Pharmaceutical, Inc. ($98.63) |
| 2017 | $587.42 | 29 | Mallinckrodt LLC ($107.39) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 03/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/11/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $104.82 | General |
| Category: Hyperkalemia | ||||||
| 08/23/2023 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Nephrology | ||||||
| 04/04/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Hyperkalemia | ||||||
| 06/04/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.37 | General |
| Category: NEPHROLOGY | ||||||
| 05/02/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Hyperparathyroidism | ||||||
| 11/29/2018 | Keryx Biopharmaceuticals, Inc. | Auryxia (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Nephrology | ||||||
| 11/28/2018 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: NEPHROLOGY | ||||||
| 11/26/2018 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/15/2018 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 10/30/2018 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Nephrology | ||||||
| 10/01/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: Hyperkalemia | ||||||
| 09/20/2018 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/05/2018 | Keryx Biopharmaceuticals, Inc. | Auryxia (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Nephrology | ||||||
| 08/30/2018 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Nephrology | ||||||
| 08/20/2018 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Gout/Rheumatology | ||||||
| 07/11/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Hyperkalemia | ||||||
| 06/19/2018 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: NEPHROLOGY | ||||||
| 06/06/2018 | Keryx Biopharmaceuticals, Inc. | Auryxia (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Nephrology | ||||||
| 05/23/2018 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/07/2018 | Horizon Pharma plc | KRYSTEXXA (Drug) | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: KRYSTEXXA | ||||||
| 05/03/2018 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: NEPHROLOGY | ||||||
| 04/30/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 2,099 | 9,623 | $652,837 | $176,234 |
| 2022 | 33 | 2,352 | 16,594 | $787,146 | $205,199 |
| 2021 | 36 | 2,482 | 14,882 | $969,044 | $269,592 |
| 2020 | 33 | 2,433 | 10,826 | $1.2M | $299,270 |
Total Patients
9,366
Total Services
51,925
Medicare Billing
$950,296
Procedure Codes
132
All Medicare Procedures & Services
132 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 38 | 213 | $220,455 | $59,010 | 26.8% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 15 | 68 | $54,400 | $15,817 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 275 | $67,100 | $14,857 | 22.1% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 172 | 309 | $38,625 | $12,337 | 31.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 77 | 172 | $29,584 | $10,332 | 34.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 27 | 44 | $39,600 | $10,134 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 91 | $22,386 | $8,231 | 36.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 26 | 1,140 | $28,500 | $6,915 | 24.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 42 | $20,538 | $5,335 | 26.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $15,776 | $4,647 | 29.5% |
| 82306 | Vitamin d-3 level | Office | 2023 | 113 | 148 | $8,880 | $4,247 | 47.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 192 | 430 | $8,600 | $3,612 | 42.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 39 | $12,831 | $3,164 | 24.7% |
| 80069 | Kidney function blood test panel | Office | 2023 | 172 | 351 | $12,285 | $2,946 | 24.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $9,648 | $2,370 | 24.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 34 | 43 | $16,770 | $2,337 | 13.9% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 160 | 296 | $5,920 | $1,856 | 31.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 169 | 303 | $12,120 | $1,527 | 12.6% |
| 84156 | Total protein level, urine | Office | 2023 | 168 | 302 | $3,322 | $1,079 | 32.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 54 | 80 | $3,560 | $1,047 | 29.4% |
| 84466 | Transferrin (iron binding protein) level | Office | 2023 | 53 | 79 | $4,424 | $967.50 | 21.9% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 19 | 4,800 | $4,800 | $797.95 | 16.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 19 | 24 | $3,120 | $591.21 | 18.9% |
| 83540 | Iron level | Office | 2023 | 54 | 80 | $2,000 | $497.04 | 24.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 41 | $2,173 | $435.42 | 20.0% |
About Dr. Jonathan Planer, MD
Dr. Jonathan Planer, MD is a Nephrology healthcare provider based in Gastonia, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699886259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Planer, MD has received a total of $1,287 in payments from pharmaceutical and medical device companies, with $149.46 received in 2024. These payments were reported across 64 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,175).
As a Medicare-enrolled provider, Planer has provided services to 9,366 Medicare beneficiaries, totaling 51,925 services with total Medicare billing of $950,296. Data is available for 4 years (2020–2023), covering 132 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Gastonia, NC
- Active Since 08/31/2006
- Last Updated 04/14/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1699886259
Products in Payments
- Veltassa (Drug) $226.65
- SAMSCA (Drug) $181.67
- Auryxia (Drug) $177.15
- ACTHAR (Biological) $124.31
- ZEPATIER (Drug) $86.00
- Parsabiv (Biological) $80.63
- ENTRESTO (Drug) $75.65
- Uloric (Drug) $75.12
- Velphoro (Drug) $52.99
- GATTEX (Drug) $25.84
- Vafseo (Drug) $24.61
- KRYSTEXXA (Drug) $22.70
- NORTHERA (Drug) $21.30
- AURYXIA (Drug) $20.37
- FARXIGA (Drug) $20.03
- Rayaldee (Drug) $16.58
- Dialyzers (Device) $15.77
- Rituxan (Biological) $14.92
- JYNARQUE (Drug) $13.86
- RAYOS (Drug) $11.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.